212 related articles for article (PubMed ID: 34156708)
1. PD-L1 expression and immune stromal features in HPV-independent cervical adenocarcinoma.
Song F; Jia M; Yu S; Cao L; Sun PL; Gao H
Histopathology; 2021 Nov; 79(5):861-871. PubMed ID: 34156708
[TBL] [Abstract][Full Text] [Related]
2. Programmed death-ligand 1 expression in human papillomavirus-independent cervical adenocarcinoma and its prognostic significance.
Chen L; Lucas E; Zhang X; Liu Q; Zhuang Y; Lin W; Chen H; Zhou F
Histopathology; 2022 Jan; 80(2):338-347. PubMed ID: 34455625
[TBL] [Abstract][Full Text] [Related]
3. PD-L1, RB1 and mismatch repair protein immunohistochemical expression in neuroendocrine carcinoma, small cell type, of the uterine cervix.
Morgan S; Slodkowska E; Parra-Herran C; Mirkovic J
Histopathology; 2019 Jun; 74(7):997-1004. PubMed ID: 30667073
[TBL] [Abstract][Full Text] [Related]
4. PD-L1 Expression in Endocervical Adenocarcinoma: Correlation With Patterns of Tumor Invasion, CD8+ Tumor-infiltrating Lymphocytes, and Clinical Outcomes.
Rivera-Colon G; Chen H; Molberg K; Niu S; Strickland AL; Castrillon DH; Carrick K; Gwin K; Lea J; Zheng W; Lucas E
Am J Surg Pathol; 2021 Jun; 45(6):742-752. PubMed ID: 33298732
[TBL] [Abstract][Full Text] [Related]
5. The Prognostic Values of HPV Genotypes and Tumor PD-L1 Expression in Patients With HPV-associated Endocervical Adenocarcinoma.
Zhou F; Chen H; Li M; Strickland AL; Zheng W; Zhang X
Am J Surg Pathol; 2022 Mar; 46(3):300-308. PubMed ID: 35175967
[TBL] [Abstract][Full Text] [Related]
6. PD-L1 Expression and CD8+ Tumor-infiltrating Lymphocytes in Different Types of Tubo-ovarian Carcinoma and Their Prognostic Value in High-grade Serous Carcinoma.
Chen H; Molberg K; Strickland AL; Castrillon DH; Carrick K; Jiang Q; Niu S; Rivera-Colon G; Gwin K; Hinson S; Lea J; Miller DS; Zheng W; Lucas E
Am J Surg Pathol; 2020 Aug; 44(8):1050-1060. PubMed ID: 32384321
[TBL] [Abstract][Full Text] [Related]
7. Prognostic impacts of the combined positive score and the tumor proportion score for programmed death ligand-1 expression by double immunohistochemical staining in patients with advanced gastric cancer.
Yamashita K; Iwatsuki M; Harada K; Eto K; Hiyoshi Y; Ishimoto T; Nagai Y; Iwagami S; Miyamoto Y; Yoshida N; Komohara Y; Ajani JA; Baba H
Gastric Cancer; 2020 Jan; 23(1):95-104. PubMed ID: 31451991
[TBL] [Abstract][Full Text] [Related]
8. PD-L1 Expression and Tumour Microenvironment Patterns in Resected Non-Small-Cell Lung Cancer.
Gurevičienė G; Matulionė J; Poškienė L; Miliauskas S; Žemaitis M
Medicina (Kaunas); 2024 Mar; 60(3):. PubMed ID: 38541208
[No Abstract] [Full Text] [Related]
9. Expression of PD-L1 and presence of CD8-positive T cells in pre-treatment specimens of locally advanced cervical cancer.
Enwere EK; Kornaga EN; Dean M; Koulis TA; Phan T; Kalantarian M; Köbel M; Ghatage P; Magliocco AM; Lees-Miller SP; Doll CM
Mod Pathol; 2017 Apr; 30(4):577-586. PubMed ID: 28059093
[TBL] [Abstract][Full Text] [Related]
10. Scoring systems for PD-L1 expression and their prognostic impact in patients with resectable gastric cancer.
Pereira MA; Ramos MFKP; Dias AR; Ribeiro R; Cardili L; Zilberstein B; Cecconello I; Ribeiro U; de Mello ES; de Castria TB
Virchows Arch; 2021 Jun; 478(6):1039-1048. PubMed ID: 33098489
[TBL] [Abstract][Full Text] [Related]
11. PD-L1 expression and survival in p16-negative and -positive squamous cell carcinomas of the vulva.
Czogalla B; Pham D; Trillsch F; Rottmann M; Gallwas J; Burges A; Mahner S; Kirchner T; Jeschke U; Mayr D; Schmoeckel E
J Cancer Res Clin Oncol; 2020 Mar; 146(3):569-577. PubMed ID: 32025868
[TBL] [Abstract][Full Text] [Related]
12. PD-L1 expression in sebaceous carcinomas.
Saliba M; Shaheen M; Hajj RE; Abbas F; Bashir S; Sheikh UN; Mahfouz R; Loya A; Khalifeh I
Cancer Immunol Immunother; 2021 Jul; 70(7):1907-1915. PubMed ID: 33398391
[TBL] [Abstract][Full Text] [Related]
13. Prognostic effect of different PD-L1 expression patterns in squamous cell carcinoma and adenocarcinoma of the cervix.
Heeren AM; Punt S; Bleeker MC; Gaarenstroom KN; van der Velden J; Kenter GG; de Gruijl TD; Jordanova ES
Mod Pathol; 2016 Jul; 29(7):753-63. PubMed ID: 27056074
[TBL] [Abstract][Full Text] [Related]
14. PD-L1 and HLA-class I expression status and their therapeutic implication in oesophageal small-cell carcinoma.
Yamashita S; Abe H; Yamashita H; Yagi K; Seto Y; Ushiku T
Histopathology; 2023 Aug; 83(2):264-275. PubMed ID: 37071391
[TBL] [Abstract][Full Text] [Related]
15. PD-L1 Expression in Endometrial Carcinoma Cells and Intratumoral Immune Cells: Differences Across Histologic and TCGA-based Molecular Subgroups.
Pasanen A; Ahvenainen T; Pellinen T; Vahteristo P; Loukovaara M; Bützow R
Am J Surg Pathol; 2020 Feb; 44(2):174-181. PubMed ID: 31651527
[TBL] [Abstract][Full Text] [Related]
16. Expression of PD-L1, indoleamine 2,3-dioxygenase and the immune microenvironment in gastric adenocarcinoma.
Patil PA; Blakely AM; Lombardo KA; Machan JT; Miner TJ; Wang LJ; Marwaha AS; Matoso A
Histopathology; 2018 Jul; 73(1):124-136. PubMed ID: 29489025
[TBL] [Abstract][Full Text] [Related]
17. Programmed cell death protein 1/programmed death ligand 1 but not HER2 is a potential therapeutic target in gastric neuroendocrine carcinoma.
Yamashita S; Abe H; Kunita A; Yamashita H; Seto Y; Ushiku T
Histopathology; 2021 Feb; 78(3):381-391. PubMed ID: 32767778
[TBL] [Abstract][Full Text] [Related]
18. Prevalence and prognostic significance of PD-L1, TIM-3 and B7-H3 expression in endometrial serous carcinoma.
Chen H; Molberg K; Carrick K; Niu S; Rivera Colon G; Gwin K; Lewis C; Zheng W; Castrillon DH; Lucas E
Mod Pathol; 2022 Dec; 35(12):1955-1965. PubMed ID: 35804040
[TBL] [Abstract][Full Text] [Related]
19. Expression of B7-H3 and TIM-3 in gastric-type endocervical adenocarcinoma: prevalence, association with PD-L1 expression, and prognostic significance.
Sun Y; Zhou X; Lucas E; Chen L; Zhang H; Chen H; Zhou F
J Pathol Clin Res; 2024 Jan; 10(1):e345. PubMed ID: 37798754
[TBL] [Abstract][Full Text] [Related]
20. Contribution of tumour and immune cells to PD-L1 expression as a predictive biomarker in metastatic triple-negative breast cancer: exploratory analysis from KEYNOTE-119.
Cortes J; Winer EP; Lipatov O; Im SA; Gonçalves A; Muñoz-Couselo E; Lee KS; Schmid P; Tamura K; Testa L; Witzel I; Ohtani S; Hund S; Kulangara K; Karantza V; Mejia JA; Ma J; Jelinic P; Huang L; Pruitt SK; Emancipator K
J Pathol Clin Res; 2024 May; 10(3):e12371. PubMed ID: 38627977
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
